云南白药：2025年上半年中药资源事业群实现对外收入9.14亿元

Core Insights - Yunnan Baiyao announced that its Traditional Chinese Medicine (TCM) resource business group achieved an external revenue of 914 million yuan in the first half of 2025, representing a year-on-year growth of approximately 6.3% [1] Group 1: Business Strategy - The company emphasizes its role as a "chain leader" in the industry, focusing on high-standard development across various aspects such as seed industry, planting, processing, marketing, and branding [1] - Yunnan Baiyao implements a "six unifications" operational model, which includes unified planting planning, unified source research and supply, unified planting standards, unified processing at the origin, unified procurement and sales, and unified management [1] Group 2: Industry Development - The company aims to build a TCM industry cluster that promotes collaborative development across the supply chain [1] - Yunnan Baiyao has established the Yunnan Medicine Enterprise Alliance and the Smart Yunnan Medicine Platform Testing Alliance, successfully exploring a development path for TCM resources characterized by "one product, one chain" [1]